Tech Company Financing Transactions

EnClear Therapies Funding Round

20/20 HealthCare Partners, Amgen Ventures and Dolby Family Ventures participated in a $10 million Series A venture round for EnClear Therapies. The round was announced by the company on 2/21/2020.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Medical Devices & Instruments

Mailing Address

65 Parker St. 3A.
Newburyport, MA 01950
USA

Phone

Undisclosed

Website

www.encleartherapies.com

Email Address

Not Recorded

Overview

EnClear Therapies was conceived by the founders of QurAlis and Q-State Bio, with the sole purpose of developing novel device-based therapies to treat patients with neurodegenerative disease. The companies first products will aim to halt the progression of ALS and PSP.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Jonathan Fleming

        

Chief Executive Officer

Anthony DePasqua

        

Chief Medical Officer

William Gormley

        

Chief Scientific Officer

Kasper Roet

        

Co-Founder

Kevin Eggan

        

VP - R & D

Kevin Kalish

        

VP - R & D

William Siopes

        

Browse more venture capital transactions:

Prev: 2/21/2020: Q Bio venture capital transaction
Next: 2/21/2020: Spruce Biosciences venture capital transaction

Share this article

Where The Data Comes From

We do our best to document every notable VC transaction. All VC database entries reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary